BridgeBio Pharma Inc (BBIO)
30.10
-0.94
(-3.04%)
USD |
NASDAQ |
May 17, 16:00
30.10
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Cash from Operations (TTM): -602.94M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -602.94M |
| December 31, 2023 | -527.72M |
| September 30, 2023 | -496.14M |
| June 30, 2023 | -486.08M |
| March 31, 2023 | -403.18M |
| December 31, 2022 | -419.49M |
| September 30, 2022 | -460.15M |
| June 30, 2022 | -446.54M |
| March 31, 2022 | -507.80M |
| December 31, 2021 | -497.93M |
| September 30, 2021 | -460.30M |
| Date | Value |
|---|---|
| June 30, 2021 | -470.42M |
| March 31, 2021 | -466.56M |
| December 31, 2020 | -399.71M |
| September 30, 2020 | -379.66M |
| June 30, 2020 | -297.97M |
| March 31, 2020 | -278.37M |
| December 31, 2019 | -253.59M |
| September 30, 2019 | -223.80M |
| June 30, 2019 | -212.12M |
| March 31, 2019 | -177.83M |
| December 31, 2018 | -136.64M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-602.94M
Minimum
Mar 2024
-212.12M
Maximum
Jun 2019
-414.52M
Average
-453.34M
Median
Cash from Operations (TTM) Benchmarks
| Pfizer Inc | 8.578B |
| Alnylam Pharmaceuticals Inc | 189.12M |
| Regenxbio Inc | -192.94M |
| ACADIA Pharmaceuticals Inc | 63.71M |
| Biomarin Pharmaceutical Inc | 280.16M |